Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. NEW YORK and MAINZ, GERMANY, July 19, 2022 — Pfizer Inc.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Pfizer

NOVEMBER 23, 2022

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™. Pfizer Signs Agreement to Provide the European Union with PAXLOVID™. Share. • New agreement to supply up to 3.4 NEW YORK, November 23, 2022 -- Pfizer Inc. Wed, 11/23/2022 - 10:54. Wednesday, November 23, 2022 - 11:00am.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

XTalks

SEPTEMBER 14, 2020

In return, these companies have promised some 300 million doses of a vaccine in an initiative the White House has called “Operation Warp Speed.”. Novavax announced it has joined the COVID-19 vaccine team supported by “Operation Warp Speed” in July. “Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

The Pharma Data

SEPTEMBER 15, 2020

Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3. New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. NEW YORK–(BUSINESS WIRE)– As part of a two-day virtual Investor Day, Pfizer Inc.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

DECEMBER 20, 2020

Many companies appear to be getting their clinical trial news updated ahead of the holidays. CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. Here’s a look. COVID-19-Related.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52